Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Clinical Cancer Research

• Publication date

  1996-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 9816224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Contribution of O6‐methylguanine‐DNA methyltransferase to resistance to 1,3‐(2‐chloroethyl)‐1‐nitrosourea in human brain tumor‐derived cell lines

  1995cited by this paper
• Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase.

  1995cited by this paper
• Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer.

  1995cited by this paper
• Antitumor imidazotetrazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide.

  1995cited by this paper
• O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide.

  1995cited by this paper
• Activity of temozolomide in the treatment of central nervous system tumor xenografts.

  1995cited by this paper
• Contribution of O6‐methylguanine‐DNA methyltransferase to monofunctional alkylating‐agent resistance in human brain tumor—derived cell lines

  1995cited by this paper
• NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA.

  1994cited by this paper
• Glutathione-associated enzymes in anticancer drug resistance.

  1994cited by this paper
• Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery.

  1994cited by this paper
• DNA damage tolerance, mismatch repair and genome instability

  1994cited by this paper
• Chemosensitisation of alkylating agents by pentoxifylline, O6-benzylguanine and ethacrynic acid in haematological malignancies.

  1993cited by this paper
• Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

  1993cited by this paper
• Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.

  1993cited by this paper
• Chemical synthesis and detection of the cross-link 1-[N3-(2'-deoxycytidyl)]-2-[N1-(2'-deoxyguanosinyl)]ethane in DNA reacted with 1-(2-chloroethyl)-1-nitrosourea.

  1993cited by this paper
• Protection against chloroethylnitrosourea cytotoxicity by eukaryotic 3-methyladenine DNA glycosylase.

  1993cited by this paper
• Expression in mammalian cells of the Escherichia coli O6 alkylguanine-DNA-alkyltransferase gene ogt reduces the toxicity of alkylnitrosoureas.

  1993cited by this paper
• DNA repair.

  1993cited by this paper
• Self-destruction and tolerance in resistance of mammalian cells to alkylation damage.

  1992cited by this paper
• Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

  1992cited by this paper
• Expression of human O6-methylguanine-DNA methyltransferase in a DNA excision repair-deficient Chinese hamster ovary cell line and its response to certain alkylating agents.

  1992cited by this paper
• Apoptosis induced by anticancer drugs

  1992cited by this paper
• Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.

  1992cited by this paper
• Incision at O6-methylguanine:thymine mispairs in DNA by extracts of human cells.

  1992cited by this paper
• 3-Methyladenine DNA glycosylase activity in a glial cell line sensitive to the haloethylnitrosoureas in comparison with a resistant cell line.

  1991cited by this paper
• Expression of human O6‐methylguanine‐DNA methyltransferase in chinese hamster ovary cells and restoration of cellular resistance to certain N‐nitroso compounds

  1991cited by this paper
• Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents.

  1991cited by this paper
• Cloning and characterization of a 3-methyladenine DNA glycosylase cDNA from human cells whose gene maps to chromosome 16.

  1991cited by this paper
• Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents.

  1991cited by this paper
• Isolation of two chloroethylnitrosourea-sensitive Chinese hamster cell lines.

  1991cited by this paper
• Saccharomyces cerevisiae 3‐methyladenine DNA glycosylase has homology to the AlkA glycosylase of E. coli and is induced in response to DNA alkylation damage.

  1990cited by this paper
• DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal.

  1990cited by this paper
• Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents.

  1990cited by this paper
• Mutagenic and recombinogenic consequences of DNA-repair inhibition during treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea in Saccharomyces cerevisiae.

  1990cited by this paper
• Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report.

  1990cited by this paper
• Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure

  1990cited by this paper
• Nitrosoureas from chemist to physician: classification and recent approaches to drug design.

  1990cited by this paper
• Comparisons between sensitive and resistant human tumor cell lines regarding effects of polyamine depletion on chloroethylnitrosourea efficacy.

  1990cited by this paper
• Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors

  1989cited by this paper
• The role of chemotherapy in the treatment of gliomas in adults.

  1989cited by this paper
• Checkpoints: controls that ensure the order of cell cycle events.

  1989cited by this paper
• Differences in DNA alkylation products formed in sensitive and resistant human glioma cells treated with N-(2-chloroethyl)-N-nitrosourea.

  1988cited by this paper
• Overexpression of metallothionein confers resistance to anticancer drugs.

  1988cited by this paper
• DNA repair enzymes.

  1988cited by this paper
• Mechanisms of carcinogenesis induced by alkylating agents.

  1985cited by this paper
• Repair of haloethylnitrosourea-induced DNA damage in mutant and adapted bacteria.

  1985cited by this paper
• Repair of Haloethylnitrosourea-induced DNA Damage in Mutant and Adapted Bacteria

  1985cited by this paper
• Molecular Biology of Mutagens and Carcinogens

  1983cited by this paper
• Biological effects of ultraviolet radiation

  1980cited by this paper

• Temozolomide-Derived Therapeutic Strategies to Overcome Resistance in Glioblastoma.

  2025cites this paper
• Differential expression of GABARAPs in glioblastoma renders temozolomide sensitivity in a p53-dependent manner.

  2025cites this paper
• Overexpression of miR-124 enhances the therapeutic benefit of TMZ treatment in the orthotopic GBM mice model by inhibition of DNA damage repair

  2025cites this paper
• High expression of LncRNA HOTAIR is a risk factor for temozolomide resistance in glioblastoma via activation of the miR-214/β-catenin/MGMT pathway

  2024cites this paper
• Differential expression of GABARAPs in GBM renders temozolomide sensitivity in a p53-dependent manner

  2024cites this paper
• Exosomes as nature's nano carriers: Promising drug delivery tools and targeted therapy for glioma.

  2024cites this paper
• Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture.

  2022cites this paper
• Polymeric and small molecule-conjugates of temozolomide as improved therapeutic agents for glioblastoma multiforme.

  2022cites this paper
• Recent developments in drug delivery strategies for targeting DNA damage response in glioblastoma.

  2021cites this paper
• The Role of Side Population Cells and Hypoxia in Resistance to Chemotherapy in Astrocytoma Cell Lines

  2021cites this paper
• DNA Repair Mechanisms and Therapeutic Targets in Glioma

  2021cites this paper
• Genotoxic therapy and resistance mechanism in gliomas.

  2021cites this paper
• Acridine-O6-benzylguanine hybrids: Synthesis, DNA binding, MGMT inhibition and antiproliferative activity.

  2021cites this paper
• The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices

  2020cites this paper
• siRNA Nanoparticle Suppresses Drug‐Resistant Gene and Prolongs Survival in an Orthotopic Glioblastoma Xenograft Mouse Model

  2020cites this paper
• Reinforcement learning for optimal scheduling of Glioblastoma treatment with Temozolomide

  2020cites this paper
• Identification of a transient state during the acquisition of temozolomide resistance in glioblastoma

  2020cites this paper
• Targeting DNA repair in gliomas.

  2019cites this paper
• Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner

  2019cites this paper
• Molecular and immunological rationale for the use of tyrosine kinase inhibitors and immune checkpoint inhibitors in glioblastomas

  2019cites this paper
• Novel multi-drugs incorporating hybrid-structured nanofibers enhance alkylating agent activity in malignant gliomas

  2019cites this paper
• MDM2 antagonist-loaded targeted micelles in combination with doxorubicin: effective synergism against human glioblastoma via p53 re-activation

  2019cites this paper
• Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma

  2018cites this paper
• Synthesis of Novel Zwitterionic Polymers: From Functional Surfactants to Therapeutics

  2018cites this paper
• Biodegradable hybrid-structured nanofibrous membrane supported chemoprotective gene therapy enhances chemotherapy tolerance and efficacy in malignant glioma rats

  2018cites this paper
• A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

  2017cites this paper
• Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner.

  2017cites this paper
• Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide‐Resistant Glioblastoma‐Initiating Cells

  2016cites this paper
• Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs

  2016cites this paper
• PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma.

  2016cites this paper
• Ultrasound-induced opening of the blood-brain barrier to enhance temozolomide and irinotecan delivery: an experimental study in rabbits.

  2016cites this paper
• Toward Personalized Therapy for Cancer

  2015cites this paper
• The role of temozolomide in the treatment of aggressive pituitary tumors.

  2015cites this paper
• Repair mechanisms help glioblastoma resist treatment.

  2015cites this paper
• Targeting DNA Repair Mechanisms to Treat Glioblastoma

  2015cites this paper
• mm 1 CHAPTER 1 Toward Personalized Therapy for Cancer

  2015cites this paper
• The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy

  2014cites this paper
• Methylation of DNA repair genes and the efficacy of DNA targeted anticancer treatment

  2014cites this paper
• O6-methylguanine-DNA methyltransferase activity is associated with response to alkylating agent therapy and with MGMT promoter methylation in glioblastoma and anaplastic glioma

  2014cites this paper
• Redox-Responsive Magnetic Nanoparticle for Targeted Convection-Enhanced Delivery of O6-Benzylguanine to Brain Tumors

  2014cites this paper
• Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.

  2014cites this paper
• Epigenetic Changes in Gliomas

  2014cites this paper
• Metabolism (Non-CYP Enzymes)

  2014cites this paper
• Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.

  2014cites this paper
• Restoration of Sensitivity in Chemo — Resistant Glioma Cells by Cold Atmospheric Plasma

  2013cites this paper
• Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)

  2013cites this paper
• Lobarstin enhances chemosensitivity in human glioblastoma T98G cells.

  2013cites this paper
• Targeted Gene Addition of Microdystrophin in Mice Skeletal Muscle via Human Myoblast Transplantation

  2013cites this paper
• Methoxyamine sensitizes the resistant glioblastoma T98G cell line to the alkylating agent temozolomide

  2013cites this paper
• Application progress of temozolomide in clinical tumor chemotherapy

  2013cites this paper
• Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-κB-dependent pathway.

  2012cites this paper
• New insights into TRPV1 function in the brain under physiological and pathological conditions

  2012cites this paper
• Top-Down Multiscale Simulation of Tumor Response to Treatment in the Context of In Silico Oncology. The Notion of Oncosimulator

  2012cites this paper
• The strategy for enhancing temozolomide against malignant glioma

  2012cites this paper
• Repair of 3-methyladenine and abasic sites by base excision repair mediates glioblastoma resistance to temozolomide

  2012cites this paper
• O(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problems.

  2012cites this paper
• Mitochondrial DNA Repair

  2011cites this paper
• Endocrine disrupting chemicals modulate expression of O⁶-methylguanine DNA methyltransferase (O⁶-MGMT) gene in the hermaphroditic fish, Kryptolebias marmoratus.

  2011cites this paper
• Expression of O6-methylguanine-DNA methyltransferase in childhood medulloblastoma

  2011cites this paper
• Expression of O 6 -methylguanine-DNA methyltransferase in childhood medulloblastoma Denis FaoroAndreO. von BuerenTarek ShalabyDavide Sciuscio • Marie-Louise HurlimannLucia ArnoldNicolas U. GerberJohannes Haybaeck • Michel MittelbronnStefan RutkowskiMonika HegiMichael A. Grotzer

  2011cites this paper
• Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma

  2011cites this paper
• Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational Applications

  2010cites this paper
• Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide

  2010influential citation
• Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models

  2010cites this paper
• Minimally Cytotoxic Doses of Temozolomide Produce Radiosensitization in Human Glioblastoma Cells Regardless of MGMT Expression

  2010cites this paper
• Temozolomide: Expanding its role in brain cancer.

  2010cites this paper
• Top-Down Multilevel Simulation of Tumor Response to Treatment in the Context of In Silico Oncology

  2010cites this paper
• In Silico Oncology Part I: Clinically Oriented Cancer Multilevel Modeling Based on Discrete Event Simulation

  2010cites this paper
• Aberrations of the Epigenome in Gliomas: Novel Targets for Therapy

  2010cites this paper
• DNA ligase IV as a new molecular target for temozolomide.

  2009cites this paper
• MGMT analysis at DNA, RNA and protein levels in glioblastoma tissue.

  2009cites this paper
• Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.

  2009cites this paper
• Phase II Trial of Gliadel plus O6-Benzylguanine in Adults with Recurrent Glioblastoma Multiforme

  2009cites this paper
• AVALIAÇÃO DA RESPOSTA CELULAR MEDIADA PELO QUIMIOTERÁPICO TEMOZOLOMIDA ASSOCIADA AO INIBIDOR DO REPARO DO DNA METOXIAMINA EM LINHAGENS DE GLIOBLASTOMA

  2009cites this paper
• Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.

  2009cites this paper
• O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

  2009cites this paper
• Phase II Trial of Gliadel plus O 6-Benzylguanine in Adults with Recurrent GlioblastomaMultiforme

  2009cites this paper
• PROCEEDINGS OF THE 12TH ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES

  2009cites this paper
• Temozolomide with Radiation Therapy in High Grade Brain Gliomas: Pharmaceuticals Considerations and Efficacy; A Review Article

  2009cites this paper
• Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma.

  2009cites this paper
• Extended-schedule dose-dense temozolomide in refractory gliomas

  2009cites this paper
• Temozolomide and cisplatin in relapsed/refractory acute leukemia

  2009cites this paper
• Heterogeneity of Human Glioblastoma: Glutathione-S-Transferase and Methylguanine-Methyltransferase

  2008cites this paper
• Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

  2008cites this paper
• Mechanistic Study on the Therapeutic Strategy to Enhance Glioma Cell Death through Inhibition of Proteasome and Lysosome

  2008cites this paper
• O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors

  2008cites this paper
• Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report

  2007cites this paper
• Human Glioma Cell Sensitivity to the Sequence-Specific Alkylating Agent Methyl-Lexitropsin

  2007cites this paper
• [Molecular pharmacology on DNA methylating agent temozolomide].

  2007cites this paper
• Temozolomide: a milestone in neuro-oncology and beyond?

  2006cites this paper
• Complications of a temozolomide overdose: a case report

  2006cites this paper
• 06-Methylguanine-DNA Methyltransferase Activity in Adult ( Â ¿ liornas : Relation to Patient and Tumor Characteristics 1

  2006cites this paper
• Simulating chemotherapeutic schemes in the individualized treatment context: The paradigm of glioblastoma multiforme treated by temozolomide in vivo

  2006cites this paper
• A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide

  2006cites this paper
• 06-Methylguanine-DNA Methyltransferase Activity in Adult ( Â ¿ liornas : Relation to Patient and Tumor Characteristics 1

  2006cites this paper
• Phase II Trial of Temozolomide and Irinotecan as Second-Line Treatment for Advanced Non–small Cell Lung Cancer

  2006cites this paper
• The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death.

  2005cites this paper
• O 6-Methylguanine-DNAMethyltransferase , O 6-Benzylguanine , and Resistance to Clinical Alkylators in Pediatric Primary BrainTumor Cell Lines

  2005cites this paper
• Chemotherapy and novel therapeutic approaches in malignant glioma.

  2005cites this paper
• O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell Lines

  2005cites this paper